Gene-edited seed developer Cibus sets terms for $100 million IPO

Shutterstock photo

Cibus, which is developing gene-editing technology for the global seed industry, announced terms for its IPO on Monday.

The San Diego, CA-based company plans to raise $100 million by offering 6.67 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Cibus would command a market value of $350 million. 

Cibus was founded in 2001 and booked $3 million in product sales and collaboration revenue for the 12 months ended September 30, 2018. It plans to list on the Nasdaq under the symbol CBUS. Morgan Stanley, BofA Merrill Lynch and Piper Jaffray are the joint bookrunners on the deal. It is expected to price during the week of February 11, 2019.

The article Gene-edited seed developer Cibus sets terms for $100 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?